Kyu-Don Kim
Corporate Officer/Principal bei GENEXINE, INC.
Profil
Kyu-Don Kim is currently the Director of Operations at PT Kalbe Genexine Biologics and the President of the Executive Board at Genexine, Inc. Previously, he worked as the Vice President, Director, and Head of Management at Chong Kun Dang Pharmaceutical Corp.
in 2014.
He holds a doctorate degree from Northern Illinois University.
Aktive Positionen von Kyu-Don Kim
| Unternehmen | Position | Beginn |
|---|---|---|
| GENEXINE, INC. | Corporate Officer/Principal | - |
PT Kalbe Genexine Biologics
 PT Kalbe Genexine Biologics BiotechnologyHealth Technology PT Kalbe Genexine Biologics is a clinical-stage biotech company based in Jakarta, Indonesia. The Indonesian company specializes in licensing novel biologics and biosimilars in oncology and high-specialty therapeutic areas, as well as contract manufacturing. The company was founded in 2016 and is backed by Kalbe and Genexine, as well as US private equity giant General. The CEO is Sie Djohan. | Geschäftsführer | - |
Ehemalige bekannte Positionen von Kyu-Don Kim
| Unternehmen | Position | Ende |
|---|---|---|
| CHONG KUN DANG PHARMACEUTICAL CORP. | Vorstandsvorsitzender | - |
Ausbildung von Kyu-Don Kim
| Northern Illinois University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CHONG KUN DANG PHARMACEUTICAL CORP. | Health Technology |
| GENEXINE, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
PT Kalbe Genexine Biologics
PT Kalbe Genexine Biologics BiotechnologyHealth Technology PT Kalbe Genexine Biologics is a clinical-stage biotech company based in Jakarta, Indonesia. The Indonesian company specializes in licensing novel biologics and biosimilars in oncology and high-specialty therapeutic areas, as well as contract manufacturing. The company was founded in 2016 and is backed by Kalbe and Genexine, as well as US private equity giant General. The CEO is Sie Djohan. | Health Technology |
